34 results
6-K
EX-10.1
IPA
ImmunoPrecise Antibodies Ltd
23 Feb 24
Current report (foreign)
5:29pm
to the date that this representation is made or deemed made.
(s) Litigation. Except as set forth in the Registration Statement and the Prospectus … or regulations of foreign jurisdictions where Shares have been offered or sold or at common law or otherwise (including in settlement of any litigation
424B5
IPA
ImmunoPrecise Antibodies Ltd
23 Feb 24
Prospectus supplement for primary offering
5:26pm
in regulatory or agency proceedings, investigations and audits;
the Company may be subject to litigation in the ordinary course of its business … intellectual property litigation;
the Company's dependence upon key personnel;
the Company may not achieve sufficient brand awareness;
the Company's
424B5
IPA
ImmunoPrecise Antibodies Ltd
7 Dec 23
Prospectus supplement for primary offering
4:53pm
be subject to litigation in the ordinary course of its business;
the ability of the Company to obtain, protect and enforce patents on its technology … become subject to patent and other intellectual property litigation;
the Company's dependence upon key personnel;
the Company may not achieve
6-K
EX-10.1
IPA
ImmunoPrecise Antibodies Ltd
6 Dec 23
Current report (foreign)
5:19pm
, and the rules and regulations of the Financial Industry Regulatory Authority, Inc. ("FINRA").
2.15[Reserved.]
2.16 Litigation; Governmental … Proceedings. There is no material action, suit, proceeding, inquiry, arbitration, investigation, litigation or governmental proceeding pending
424B5
IPA
ImmunoPrecise Antibodies Ltd
5 Dec 23
Prospectus supplement for primary offering
4:02pm
proceedings, investigations and audits;
the Company may be subject to litigation in the ordinary course of its business;
the ability of the Company … requirements set forth in client contracts;
the Company may become subject to patent and other intellectual property litigation;
the Company's
6-K
EX-10.1
j8n3a80gf
15 Aug 23
Current report (foreign)
5:50pm
424B5
bf0sgdfo upp2p
15 Aug 23
Prospectus supplement for primary offering
5:47pm
F-3
5tbw6ev08oe
10 Jul 23
Shelf registration (foreign)
7:04pm
40-F
EX-99.1
2iy q65xlt
10 Jul 23
Annual report (Canada)
4:32pm
40-F
zr5o zgseuvlgk5u
10 Jul 23
Annual report (Canada)
4:32pm
40-F
EX-99.3
9pvkccvqp zmryt3s
10 Jul 23
Annual report (Canada)
4:32pm
40-F
q8rzu1g
29 Jul 22
Annual report (Canada)
9:04am
40-F
EX-99.3
005k5xmud8rs5
29 Jul 22
Annual report (Canada)
9:04am
40-F
EX-99.1
idp3p09
29 Jul 22
Annual report (Canada)
9:04am
6-K
EX-99.2
xgwm0
14 Apr 22
Current report (foreign)
10:18am
6-K
EX-99.1
cvd2dp2qglgzp8oif
20 Dec 21
Immunoprecise Antibodies LTD. 6-K
8:01am
6-K
EX-99.1
fzyoqit
30 Nov 21
Immunoprecise Antibodies LTD. 6-K
8:01am
6-K
EX-99.2
kew07wod7vvk4f73
13 Oct 21
ImmunoPrecise Announces At-The-Market Facility of up to US$50 Million
5:31pm
SUPPL
2rizcv6r093zusjood4
13 Oct 21
Supplemental materials (foreign)
5:29pm
40-F
EX-99.1
tbj5jtngj3vrlycawy9
28 Jul 21
Annual report (Canada)
8:01am